KOMPLEKSNYY PODKhOD K TERAPII BOLI S PRIMENENIEM KSEFOKAMA (LORNOKSIKAMA) PRI OSTEOARTROZE
- Authors: Dydykina I.S1, Dydykina P.S1
-
Affiliations:
- Issue: No 7 (2014)
- Pages: 62-67
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/286905
- ID: 286905
Cite item
Open Access
Access granted
Abstract
The article discusses the problem of comprehensive approach to the treatment of patients with osteoarthrosis (OA), the need for simultaneous use of drugs for the relief of pain and inflammation in the joints, and protracted use of chondroprotectors and orthopaedic appliances, physiotherapy and rehabilitation treatment. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the drugs of choice in the treatment of pain in OA. Knowledge and observance of the fundamental principles when choosing NSAIDs allow to prevent the occurrence of major adverse reactions. Lornoxicam (Xefocam) is one of the modern NSAIDs with proven efficacy and safety for the treatment of patients with OA. The clinical case of patient with OA for a long time is presented.
Full Text
References
- Фоломеева О.М., Амирджанова В.Н., Якушева Е.О. и др. Анализ структуры XIII класса болезней // Рос. ревматол. 1998;1:2-7.
- Saase van Romunde L., Cats A., et al. Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Ann. Rheum. Dis. 1989;48(4):271-80.
- Ehrlich G.E. Osteoarthritis beginning with inflammation: definitions and correlations. J. Am. Med. Associat. 1975;232:157-59.
- Goldring M.B., Otero M. Inflammation in osteoarthritis. Curr. Opin. Rheumatol. 2011;23(5):471-78.
- Wildi L., Raynauld J., Martel-Pelletier J., et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MR!. Ann. Rheum. Dis. 2011;70:982-89.
- Killock D. Experimental arthritis: NGF promotes synovial nerve sprouting. Nature Reviews Rheumatology. 2012;8(124). doi:10.1038/ nrrheum.2012.6
- Sawitzke A.D., Shi H., Finco M.F., et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann. Rheum. Dis. 2010;69(8):1459-64.
- Scanzello C.R., Moskowitz N.K., Gibofsky A. The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. Curr. Rheumatol. Rep. 2008;10(1):49-56.
- Wolfe F., Zhao S., Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthrit. Rheum.2000;43(2):378-85.
- Skjodt N.M., Davies N.M. Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. Clin. Pharmacokinet 1998;34(6):421-28.
- Olkkola K.T., Brunetto A.V., Mattila M.J. Pharmacokinetics of oxicam nonsteroidal antiinflammatory agents. Clin. Pharmacokinet. 1994;26(2):107-20.
- Ankier S.I., Brimelow A.E., Crome P., et al. Chlortenoxicam pharmacokinetics in young and elderly human volunteers. Postgrad Med. J. 1988;64(756):752-54.
- Balfour J.A., Fitton A., Barradell L.B. Lornoxicam. A review of its pharmacology and therapeu tic potential in the management of painful and inflammatory conditions. Drugs. 1996;51(4):639-57.
- Berry H., Bird H.A., Black C., et al. A double blind, multicentre, placebo controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee. Ann. Rheum. Dis. 1992;51(2):238-42.
- Kidd B., Frenzel W. A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis. J. Rheumatol. 1996;23(9):1605-11.
- Nycomed. Xefocam® Монография. medi.ru. 2008. 03.
- Алексеева Л.И., Цветкова Е.С. Остеоартроз: из прошлого будущего. Научно-практическая ревматология. 2009;2:31-7.
- Beadle C., Howie C.R., Nuki, G., et al. OARSI Recommendations for the Management of Hip and Knee Osteoarthritis: Which Treaments are Being Used? Audit of Patients Coming to Arthroplasty in Scotland. OA & Cartil. 2010;18(suppl 2);S45-S256, abst #343.
- Zhang W., Nuki G., Moskowitz R., et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. OA Cartil. 2010;18(4):476-99.
Supplementary files
